Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up

 
• By Jessica Merrill
  
COVID-19 graphic
Phase III data on Vir/GSK's antibody against COVID-19 is expected in Q1 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip